Development of Ad-mda7/IL-24-resistant lung cancer cell lines
Graduate School of Biomedical Sciences
Life Sciences | Medicine and Health Sciences
Many cancers can become resistant to repeated administration of even the most effective therapeutic agents. In developing adenoviral mda-7/IL-24 (Ad-mda-7/IL-24) therapy for lung cancer, we have anticipated this potential clinical problem by attempting to identify the molecular mechanisms of Ad-mda7/IL-24 resistance in several Ad-mda7/IL-24-resistant lung cancer cell lines that we have developed. For the present study, we established four Admda7- resistant cell lines by repeated selection of resistant clones of parental Ad-mda7-sensitive A549 cells: two lines (A549R1 and A549R2) resistant to both adenoviral vector and the mda-7 gene and two (A549R3 and A549R4) resistant to the therapeutic mda-7 gene only. As shown by western blot analysis of several known anti-apoptotic proteins, parental A549 and resistant A549R3 cells expressed similar levels of AKT and phosphorylated AKT (p-AKT), whereas resistant A549R3 and A549R4 cells expressed higher levels of bcl-2 and lower levels of bcl-xL than did their parental cells. As shown by flow-cytometric analysis, treating resistant A549R3 and A549R4 cells with a combination of Ad-mda7 and 17-allyl-amino-17-demethoxygeldanamycin (17AAG) (50 nM) for 48 hours enhanced apoptosis. Together, these in vitro findings indicate that an antiapoptotic mechanism may underlie Ad-mda7 resistance and that such resistance can be overcome by addition of 17AAG. Further investigations along these lines are warranted.
DOI of Published Version
Cancer Biol Ther. 2008 Jan;7(1):103-8. Epub 2007 Oct 13.
Cancer biology and therapy
Pataer A, Chada S, Roth JA, Hunt KK, Swisher SG. (2007). Development of Ad-mda7/IL-24-resistant lung cancer cell lines. GSBS Student Publications. https://doi.org/10.4161/cbt.7.1.5162. Retrieved from https://escholarship.umassmed.edu/gsbs_sp/348